pyridoxal phosphate has been researched along with Parkinson Disease in 12 studies
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).
pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiparkinsonian drug L-dopa causes increased cellular synthesis of homocysteine and consequent hyperhomocysteinemia in rats." | 5.10 | Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. ( Feldman, RG; Miller, JW; Nadeau, MR; Selhub, J; Thomas, CA; Wolf, PA, 2003) |
| "Pyridoxine metabolism was investigated in eight chronic levodopa-treated parkinsonian patients and in eight matched dopa-naive controls by measurement of plasma and erythrocyte pyridoxal-5-phosphate concentrations over a 24-hour period, following intravenous administration of pyridoxine." | 1.25 | Effect of chronic levodopa treatment on pyridoxine metabolism. ( Mars, H, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, JW | 1 |
| Selhub, J | 1 |
| Nadeau, MR | 1 |
| Thomas, CA | 1 |
| Feldman, RG | 1 |
| Wolf, PA | 1 |
| Morales, I | 1 |
| Dopico, JG | 1 |
| Sabate, M | 1 |
| Gonzalez-Hernandez, T | 1 |
| Rodriguez, M | 1 |
| Botteri, A | 1 |
| Hamfelt, A | 1 |
| Söderhjelm, L | 1 |
| Mars, H | 1 |
| Sandler, M | 1 |
| Tran, N | 1 |
| Papeschi, R | 1 |
| Molina-Negro, P | 1 |
| Sourkes, TL | 1 |
| Erba, G | 1 |
| Antón-Tay, F | 1 |
| Yahr, MD | 1 |
| Duvoisin, RC | 1 |
| Côté, L | 1 |
| Cohen, G | 1 |
| Pfeiffer, R | 1 |
| Ebadi, M | 1 |
| Kurtz, DJ | 1 |
| Kanfer, JN | 1 |
| Vogel, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Vitamin Supplementation and Strength Training in Parkinson's Disease[NCT01238926] | 40 participants (Anticipated) | Interventional | 2008-05-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pyridoxal phosphate and Parkinson Disease
| Article | Year |
|---|---|
Melatonin: effects on brain function.
Topics: Adenylyl Cyclases; Aminobutyrates; Animals; Behavior; Brain; Cerebral Cortex; Cyclic AMP; Electric S | 1974 |
Pyridoxine, DOPA, and Parkinsonism.
Topics: Administration, Oral; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Antagonism; Drug Intera | 1972 |
2 trials available for pyridoxal phosphate and Parkinson Disease
| Article | Year |
|---|---|
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Topics: Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Line | 2003 |
Pyridoxine, DOPA, and Parkinsonism.
Topics: Administration, Oral; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Antagonism; Drug Intera | 1972 |
9 other studies available for pyridoxal phosphate and Parkinson Disease
| Article | Year |
|---|---|
Substantia nigra osmoregulation: taurine and ATP involvement.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Adenosine Triphosphate; Animals; Choline; Dose-Response Relati | 2007 |
Pyridoxal phosphate, tryptophan, and tyrosine in blood and cerebrospinal fluid in elderly patients.
Topics: Adult; Age Factors; Aged; Humans; Hydrocephalus; Middle Aged; Parkinson Disease; Pyridoxal Phosphate | 1984 |
Effect of chronic levodopa treatment on pyridoxine metabolism.
Topics: Aged; Erythrocytes; Humans; Levodopa; Middle Aged; Parkinson Disease; Plasma; Pyridoxal Phosphate; P | 1975 |
How does L-dopa work in parkinsonism?
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Blood-Brain Barrier; Dihydroxyphenylalanine; Dopa Deca | 1971 |
L-Dopa and pyridoxine.
Topics: Decarboxylation; Dihydroxyphenylalanine; Dopamine; Humans; Oxidation-Reduction; Parkinson Disease; P | 1972 |
The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Cerebral Palsy; Cerebral Ventricles; Diazepam; Dihydroxyp | 1972 |
On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Benzyl Compounds; Dihydroxyphe | 1972 |
L-DOPA: effect on cerebral pyridoxal phosphate content and coenzyme activity.
Topics: Animals; Brain; Carboxy-Lyases; Cerebral Cortex; Coenzymes; Dihydroxyphenylalanine; Dopamine; Glutam | 1971 |
Non-enzymatic decarboxylation of dihydroxypheylalanine.
Topics: 5-Hydroxytryptophan; Carbon Dioxide; Carbon Isotopes; Chemical Phenomena; Chemistry; Copper; Dihydro | 1969 |